CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Capecitabine

卡培他滨 杂质对照品Capecitabine Impurities

EPUSP45 个杂质条目45 impurity entries

本页汇总 卡培他滨 的 45 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 45 impurity reference standards of Capecitabine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 卡培他滨(Capecitabine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesHarnessing Pillar[5]arene Host-Guest Complexation To Improve pH Stability and Affect Enzymatic Degradation of the Anticancer Prodrug Capecitabine: A (19) F NMR Study
    Chemistry (Weinheim an der Bergstrasse, Germany) · 2023 · Horin I et al.  ·  PMID 37303257  ·  DOI
  2. 杂质研究Impurity studiesAn APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma
    Journal of mass spectrometry : JMS · 2010 · Montange D et al.  ·  PMID 20527036  ·  DOI
  3. 杂质研究Impurity studiesCytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells
    Molecular biology reports · 2011 · Wisniewska-Jarosinska M et al.  ·  PMID 21107724  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and Validation of Chemometrics-Assisted Green UPLC-MS/MS Bioanalytical Method for Simultaneous Estimation of Capecitabine and Lapatinib in Rat Plasma
    Journal of chromatographic science · 2022 · Alrobaian M et al.  ·  PMID 34318311  ·  DOI
  5. 分析方法Analytical MethodsDevelopment and Validation of a Spectrofluorimetric Method for the Quantification of Capecitabine in Bulk and Tablets
    Turkish journal of pharmaceutical sciences · 2023 · Naraparaju S et al.  ·  PMID 37606008  ·  DOI

卡培他滨 —— 原料药与杂质对照品Capecitabine — drug substance & impurities

共 46 个条目(含原料药本体)46 items incl. the drug substance
Capecitabine structure
EP原料药 APIAPI
卡培他滨Capecitabine
Capecitabine
CAS No.154361-50-9
Chemical FormulaC15H22FN3O6
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 16 (Capecitabine EP Impurity B) structure
EPB
卡培他滨杂质16 (卡培他滨EP杂质B)Capecitabine Impurity 16 (Capecitabine EP Impurity B)
Capecitabine Impurity 16 (Capecitabine EP Impurity B)
CAS No.3094-09-5
Chemical FormulaC9H11FN2O5
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 13 (Capecitabine EP Impurity C) structure
EPC
卡培他滨杂质13 (卡培他滨EP杂质C)Capecitabine Impurity 13 (Capecitabine EP Impurity C)
Capecitabine Impurity 13 (Capecitabine EP Impurity C)
CAS No.161599-46-8
Chemical FormulaC13H16FN3O6
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 2 (Capecitabine EP Impurity D) structure
EPD
卡培他滨杂质2 (卡培他滨EP杂质D)Capecitabine Impurity 2 (Capecitabine EP Impurity D)
Capecitabine Impurity 2 (Capecitabine EP Impurity D)
CAS No.910129-15-6
Chemical FormulaC15H22FN3O6
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 3(Capecitabine EP Impurity E) structure
EPE
卡培他滨杂质3(卡培他滨EP杂质E)Capecitabine Impurity 3(Capecitabine EP Impurity E)
Capecitabine Impurity 3(Capecitabine EP Impurity E)
CAS No.162204-30-0
Chemical FormulaC15H22FN3O6
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 8 (Capecitabine EP Impurity F) structure
EPF
卡培他滨杂质8 (卡培他滨EP杂质F)Capecitabine Impurity 8 (Capecitabine EP Impurity F)
Capecitabine Impurity 8 (Capecitabine EP Impurity F)
CAS No.921769-65-5
Chemical FormulaC16H20FN3O7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 7 (Capecitabine EP Impurity G) structure
EPG
卡培他滨杂质7 (卡培他滨EP杂质G)Capecitabine Impurity 7 (Capecitabine EP Impurity G)
Capecitabine Impurity 7 (Capecitabine EP Impurity G)
CAS No.162204-20-8
Chemical FormulaC19H26FN3O8
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 4 (Capecitabine USP Related Compound I) structure
USPI
卡培他滨杂质4 (卡培他滨USP相关化合物I)Capecitabine Impurity 4 (Capecitabine USP Related Compound I)
Capecitabine Impurity 4 (Capecitabine USP Related Compound I)
CAS No.1262133-68-5
Chemical FormulaC20H30FN3O9
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 1 structure
1
卡培他滨杂质1Capecitabine Impurity 1
Capecitabine Impurity 1
CAS No.66335-38-4
Chemical FormulaC9H12FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 5 structure
5
卡培他滨杂质5Capecitabine Impurity 5
Capecitabine Impurity 5
CAS No.1262133-66-3
Chemical FormulaC20H30FN3O9
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 6 structure
6
卡培他滨杂质6Capecitabine Impurity 6
Capecitabine Impurity 6
CAS No.1262133-64-1
Chemical FormulaC20H30FN3O9
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 12 structure
12
卡培他滨杂质12Capecitabine Impurity 12
Capecitabine Impurity 12
CAS No.296248-49-2
Chemical FormulaC11H14FN3O6
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 17 structure
17
卡培他滨杂质17Capecitabine Impurity 17
Capecitabine Impurity 17
CAS No.38838-05-0
Chemical FormulaC9H15BrO5
Purity>95%现货In stock
10mg25mg50mg100mg
Capecitabine Impurity 18 structure
18
卡培他滨杂质18Capecitabine Impurity 18
Capecitabine Impurity 18
CAS No.862508-03-0
Chemical FormulaC10H14FN3O3
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 19 structure
19
卡培他滨杂质19Capecitabine Impurity 19
Capecitabine Impurity 19
CAS No.1262133-70-9
Chemical FormulaC17H24FN3O7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 20 structure
20
卡培他滨杂质20Capecitabine Impurity 20
Capecitabine Impurity 20
CAS No.1262133-69-6
Chemical FormulaC17H24FN3O7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 21 structure
21
卡培他滨杂质21Capecitabine Impurity 21
Capecitabine Impurity 21
CAS No.76497-54-6
Chemical FormulaC11H16O7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 22 structure
22
卡培他滨杂质22Capecitabine Impurity 22
Capecitabine Impurity 22
CAS No.62211-93-2
Chemical FormulaC11H16O7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 25 structure
25
卡培他滨杂质25Capecitabine Impurity 25
Capecitabine Impurity 25
CAS No.613-83-2
Chemical FormulaC5H10O5
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 26 structure
26
卡培他滨杂质26Capecitabine Impurity 26
Capecitabine Impurity 26
CAS No.72402-14-3
Chemical FormulaC9H16O5
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 27 structure
27
卡培他滨杂质27Capecitabine Impurity 27
Capecitabine Impurity 27
CAS No.13007-50-6
Chemical FormulaC16H22O7S
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 28 structure
28
卡培他滨杂质28Capecitabine Impurity 28
Capecitabine Impurity 28
CAS No.78341-97-6
Chemical FormulaC9H16O4
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 29 structure
29
卡培他滨杂质29Capecitabine Impurity 29
Capecitabine Impurity 29
CAS No.1480-96-2
Chemical FormulaC5H5FN2O2
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 30 structure
30
卡培他滨杂质30Capecitabine Impurity 30
Capecitabine Impurity 30
CAS No.1801-06-5
Chemical FormulaC5H4ClFN2O
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 31 structure
31
卡培他滨杂质31Capecitabine Impurity 31
Capecitabine Impurity 31
CAS No.1993-63-1
Chemical FormulaC5H6FN3O
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 36 structure
36
卡培他滨杂质36Capecitabine Impurity 36
Capecitabine Impurity 36
CAS No.128963-10-0
Chemical FormulaC15H18FN3O8
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 37 structure
37
卡培他滨杂质37Capecitabine Impurity 37
Capecitabine Impurity 37
CAS No.6984-55-0
Chemical FormulaC12H16N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 39 structure
39
卡培他滨杂质39Capecitabine Impurity 39
Capecitabine Impurity 39
CAS No.23202-81-5
Chemical FormulaC9H16O4
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 40 structure
40
卡培他滨杂质40Capecitabine Impurity 40
Capecitabine Impurity 40
CAS No.5636-04-4
Chemical FormulaC16H18N4O4
Purity>95%现货In stock
10mg25mg50mg100mg
Capecitabine Impurity 43 structure
43
卡培他滨杂质43Capecitabine Impurity 43
Capecitabine Impurity 43
CAS No.1313238-38-8
Chemical FormulaC25H36FN3O10
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 45 structure
45
卡培他滨杂质45Capecitabine Impurity 45
Capecitabine Impurity 45
CAS No.38838-07-2
Chemical FormulaC9H15ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 46 structure
46
卡培他滨杂质46Capecitabine Impurity 46
Capecitabine Impurity 46
CAS No.34980-66-0
Chemical FormulaC5H11O8P
Purity>95%现货In stock
10mg25mg50mg100mg
Capecitabine Impurity 51 structure
51
卡培他滨杂质51Capecitabine Impurity 51
Capecitabine Impurity 51
CAS No.2265218-64-0
Chemical FormulaC22H28FN3O11
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 55 structure
55
卡培他滨杂质55Capecitabine Impurity 55
Capecitabine Impurity 55
CAS No.4099-85-8
Chemical FormulaC9H16O5
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 56 structure
56
卡培他滨杂质56Capecitabine Impurity 56
Capecitabine Impurity 56
CAS No.4137-56-8
Chemical FormulaC16H22O7S
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 60 structure
60
卡培他滨杂质60Capecitabine Impurity 60
Capecitabine Impurity 60
CAS No.1341231-51-3
Chemical FormulaC19H26FN3O8
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 61 structure
61
卡培他滨杂质61Capecitabine Impurity 61
Capecitabine Impurity 61
CAS No.162204-22-0
Chemical FormulaC19H26FN3O8
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 62 structure
62
卡培他滨杂质62Capecitabine Impurity 62
Capecitabine Impurity 62
CAS No.221171-41-1
Chemical FormulaC8H16O3
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 65 structure
65
卡培他滨杂质65Capecitabine Impurity 65
Capecitabine Impurity 65
CAS No.10074-18-7
Chemical FormulaC7H15N2O8P
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 66 structure
66
卡培他滨杂质66Capecitabine Impurity 66
Capecitabine Impurity 66
CAS No.185453-73-0
Chemical FormulaC11H15ClO7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 68 structure
68
卡培他滨杂质68Capecitabine Impurity 68
Capecitabine Impurity 68
CAS No.37076-71-4
Chemical FormulaC11H16O7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 69 structure
69
卡培他滨杂质69Capecitabine Impurity 69
Capecitabine Impurity 69
CAS No.63903-44-6
Chemical FormulaC11H16O7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 70 structure
70
卡培他滨杂质70Capecitabine Impurity 70
Capecitabine Impurity 70
CAS No.1214720-94-1
Chemical FormulaC11H16O7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 71 structure
71
卡培他滨杂质71Capecitabine Impurity 71
Capecitabine Impurity 71
CAS No.202119-71-9
Chemical FormulaC11H16O7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 72 structure
72
卡培他滨杂质72Capecitabine Impurity 72
Capecitabine Impurity 72
CAS No.202119-67-3
Chemical FormulaC11H16O7
Purity>95%询价On request
10mg25mg50mg100mg
Capecitabine Impurity 73 structure
73
卡培他滨杂质73Capecitabine Impurity 73
Capecitabine Impurity 73
CAS No.193526-80-6
Chemical FormulaC11H16O7
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

卡培他滨 —— 研究文献与合成路线Capecitabine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 卡培他滨 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Capecitabine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Harnessing Pillar[5]arene Host-Guest Complexation To Improve pH Stability and Affect Enzymatic Degradation of the Anticancer Prodrug Capecitabine: A 19 F NMR Study
    Horin I, Slovak S, Cohen Y · Chemistry (Weinheim an der Bergstrasse, Germany) · 2023 · 被引 2cited 2
  2. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine
    Roberto M, Romiti A, Botticelli A, et al. · European journal of clinical pharmacology · 2017 · 被引 14cited 14
  3. Degradation performance and potential protection mechanism of the anammox consortia in response to capecitabine
    Wang X, Chen D, Zhou Y, et al. · Chemosphere · 2023 · 被引 3cited 3
  4. A sustainable RP-HPLC method for concurrent estimation of capecitabine and celecoxib in liposomal formulation: Greenness and whiteness appraisal
    Shewale RS, Gomte SS, Jain A · Archiv der Pharmazie · 2024 · 被引 4cited 4
  5. Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL)
    Knikman JE, de Vries N, Rosing H, et al. · Die Pharmazie · 2023 · 被引 2cited 2
  6. Stopped-flow chemiluminescence determination of the anticancer drug capecitabine: Application in pharmaceutical analysis and drug-delivery systems
    Niazi Saei J, Mokhtari A, Mokhtari A, et al. · Luminescence : the journal of biological and chemical luminescence · 2020 · 被引 2cited 2

合成与制备工艺专利Synthesis & process patents

  1. PREPARATION OF CAPECITABINE
    KADABOINA RAJASEKHAR, NARIYAM SEKHAR MUNASWAMY, MURKI VEERENDER, VINJAMURI RAGHUPATI RAMA, et al. · 公开号 US2011224422US2011224422 · 2011
  2. ONE STEP PROCESS FOR THE PREPARATION OF CAPECITABINE
    GORE VINAYAK GOVIND, PATKAR LAXMIKANT NARAHARI, BHALERAO RAHUL, HUBLIKAR MAHESH GORAKHNATH, et al. · 公开号 WO2011104540WO2011104540 · 2011
  3. PROCESS FOR PREPARING CAPECITABINE
    NARIYAM SEKHAR MUNASWAMY, RAGHAVEN-DRACHARYULU, MARATHE ANANT MADHAVRAO, ALURU SRINIVAS, et al. · 公开号 MX2009011255MX2009011255 · 2009
  4. A CAPECITABINE HYDROXYL-DERIVATIVE, ITS PREPARATION PROCESSES AND USES FOR PREPARING CAPECITABINE
    JIANG XIANGRUI, CHEN WEIMING, HE XIUJUN, OU YANG, et al. · 公开号 WO2009094847WO2009094847 · 2009
  5. AN IMPROVED PROCESS FOR THE PREPARATION OF CAPECITABINE
    KANNAN VISHWANATH · 公开号 WO2010061402WO2010061402 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

卡培他滨 杂质谱研究要点Capecitabine — impurity profiling notes

下面这些是拿到 卡培他滨 的 46 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 46 impurity entries for Capecitabine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances